Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRUP trial
2023-509152-33-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorlatinib, sunitinib, amivantamab, dabrafenib + trametinib, entrectinib and 33 more in advanced nonhematological malignancy, multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and 2 more, sponsored by Netherlands Cancer Institute. Primary endpoints: Percentage of patients treated based on molecular tumor profile, Objective tumor response and 2 more. Planned start Mar 2024; status: authorised.
02
Drugs
lorlatinibsunitinibamivantamabdabrafenib + trametinibentrectinib
03
Conditions
advanced nonhematological malignancymultiple myeloma (MM)non-Hodgkin lymphoma (NHL)T-cell prolymphocytic leukemia (T-PLL)primary brain neoplasm
Beyond the preview
Go deeper on 2023-509152-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509152-33-00.